This preprint is under consideration at Lipids in Health and Disease. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Elucidating the mechanism by which regulating spleen and lipid method improves the state of hyperlipidaemic rats
Guirong Liu
Shandong University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9827-6811
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgound Hyperlipidemia has been highlighted as global chronic conditions of our time, the regulating spleen and lipid decoction (RSLD) is a traditional Chinese medicine preparation for hyperlipidemia with good therapeutic effect. This study used urinary metabolomics combined with network pharmacology to elucidate the mechanism of RSLD in treating hyperlipidemia.
Methods In this study, the network pharmacology was used to dissect the impacts of RSLD on the hyperlipidemia network. Serum samples from hyperlipidaemic rats were collected to quantify biochemical indices, urinary metabolomics was used to evaluate urine samples from control, model, xuezhikang and RSLD groups to shed light on a metabolic mechanism of action.
Results The component- target-disease network suggested that the low density lipoprotein receptor (LDLR) target protein, which is associated with hyperlipidemia, is regulated by RSLD. A metabolomics analysis suggested that RSLD can significantly regulates taurine, citric acid, leucine, valine and linoleic acid in amino acid metabolism, fatty acid metabolism and tricarboxylic acid cycle, and that the overall metabolic mechanism is closely related to the target protein LDLR.
Conclusions Metabolomics combined with network pharmacology suggested that RSLD can improve hyperlipidemia by enhancing LDLR protein expression to regulate disordered biomarkers and their metabolic pathways. Therefore, we believe that RSLD represents an interesting candidate for further characterization as a treatment for hyperlipidemia.
Keywords
the regulating spleen and lipid decoction (RSLD), hyperlipidemia, metabolomics, network pharmacology, UPLC-ESI-QTOF-MS
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 30 Dec, 2019
No community comments so far
Editorial decision: Major revision
On 27 Mar, 2020
Review #5 received
Received 21 Mar, 2020
Reviewer #5 agreed
On 03 Mar, 2020
Review #3 received
Received 13 Feb, 2020
Reviewer #4 agreed
On 10 Feb, 2020
Reviewer #3 agreed
On 04 Feb, 2020
Review #1 received
Received 22 Jan, 2020
Reviewer #2 agreed
On 22 Jan, 2020
Review #2 received
Received 22 Jan, 2020
Reviewer #1 agreed
On 02 Jan, 2020
Reviewers invited
Invitations sent on 01 Jan, 2020
Editor assigned
On 19 Dec, 2019
Submission checks complete
On 18 Dec, 2019
Editor invited
On 18 Dec, 2019
First submitted
On 15 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Lipids in Health and Disease. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Elucidating the mechanism by which regulating spleen and lipid method improves the state of hyperlipidaemic rats
Guirong Liu
Shandong University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9827-6811
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 30 Dec, 2019
No community comments so far
Editorial decision: Major revision
On 27 Mar, 2020
Review #5 received
Received 21 Mar, 2020
Reviewer #5 agreed
On 03 Mar, 2020
Review #3 received
Received 13 Feb, 2020
Reviewer #4 agreed
On 10 Feb, 2020
Reviewer #3 agreed
On 04 Feb, 2020
Review #1 received
Received 22 Jan, 2020
Reviewer #2 agreed
On 22 Jan, 2020
Review #2 received
Received 22 Jan, 2020
Reviewer #1 agreed
On 02 Jan, 2020
Reviewers invited
Invitations sent on 01 Jan, 2020
Editor assigned
On 19 Dec, 2019
Submission checks complete
On 18 Dec, 2019
Editor invited
On 18 Dec, 2019
First submitted
On 15 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgound Hyperlipidemia has been highlighted as global chronic conditions of our time, the regulating spleen and lipid decoction (RSLD) is a traditional Chinese medicine preparation for hyperlipidemia with good therapeutic effect. This study used urinary metabolomics combined with network pharmacology to elucidate the mechanism of RSLD in treating hyperlipidemia.
Methods In this study, the network pharmacology was used to dissect the impacts of RSLD on the hyperlipidemia network. Serum samples from hyperlipidaemic rats were collected to quantify biochemical indices, urinary metabolomics was used to evaluate urine samples from control, model, xuezhikang and RSLD groups to shed light on a metabolic mechanism of action.
Results The component- target-disease network suggested that the low density lipoprotein receptor (LDLR) target protein, which is associated with hyperlipidemia, is regulated by RSLD. A metabolomics analysis suggested that RSLD can significantly regulates taurine, citric acid, leucine, valine and linoleic acid in amino acid metabolism, fatty acid metabolism and tricarboxylic acid cycle, and that the overall metabolic mechanism is closely related to the target protein LDLR.
Conclusions Metabolomics combined with network pharmacology suggested that RSLD can improve hyperlipidemia by enhancing LDLR protein expression to regulate disordered biomarkers and their metabolic pathways. Therefore, we believe that RSLD represents an interesting candidate for further characterization as a treatment for hyperlipidemia.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10